NASDAQ:NURO NeuroMetrix (NURO) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free NURO Stock Alerts $3.69 -0.03 (-0.81%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$3.69▼$3.8450-Day Range$3.51▼$4.7052-Week Range$2.70▼$9.20Volume3,508 shsAverage Volume6,705 shsMarket Capitalization$7.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get NeuroMetrix alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About NeuroMetrix Stock (NASDAQ:NURO)NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Read More NURO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NURO Stock News HeadlinesJune 14 at 4:56 AM | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.comJune 5, 2024 | americanbankingnews.comNeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.comMay 15, 2024 | globenewswire.comNeuroMetrix Reports Q1 2024 Business HighlightsApril 24, 2024 | finance.yahoo.comNeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This YearApril 20, 2024 | investing.comNeuroMetrix appoints new board director, ends ATM facilityApril 19, 2024 | markets.businessinsider.comNeuroMetrix Rises 18% After Announcement Of Shareholder Value Enhancement StepsApril 19, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueApril 19, 2024 | globenewswire.comNeuroMetrix Announces Steps Taken to Enhance Shareholder ValueMarch 14, 2024 | globenewswire.comNeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyMarch 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell FibromyalgiaMarch 13, 2024 | globenewswire.comNeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaMarch 8, 2024 | finanznachrichten.deRS Fund Management LLC: RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.March 8, 2024 | finance.yahoo.comRS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc.February 25, 2024 | au.lifestyle.yahoo.comGoogle releases new open LLMs, Rivian lays off staff and Signal rolls out usernamesFebruary 24, 2024 | finance.yahoo.comNeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022)February 23, 2024 | finance.yahoo.comNeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | finance.yahoo.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 22, 2024 | globenewswire.comNeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsFebruary 15, 2024 | finance.yahoo.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 15, 2024 | globenewswire.comNeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallFebruary 13, 2024 | finanznachrichten.deNeuroMetrix, Inc.: NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueFebruary 13, 2024 | markets.businessinsider.comNeuroMetrix Plans Strategic Options To Promote Growth, Maximize Shareholder Value; Stock DropsFebruary 13, 2024 | finance.yahoo.comNeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueJanuary 8, 2024 | finance.yahoo.comNeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024See More Headlines Receive NURO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/15/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NURO CUSIPN/A CIK1289850 Webwww.neurometrix.com Phone(781) 890-9989Fax302-636-5454Employees26Year Founded1996Profitability EPS (Most Recent Fiscal Year)($6.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,530,000.00 Net Margins-151.51% Pretax Margin-151.49% Return on Equity-39.85% Return on Assets-37.08% Debt Debt-to-Equity RatioN/A Current Ratio10.91 Quick Ratio10.11 Sales & Book Value Annual Sales$5.90 million Price / Sales1.26 Cash FlowN/A Price / Cash FlowN/A Book Value$13.18 per share Price / Book0.28Miscellaneous Outstanding Shares2,010,000Free Float1,864,000Market Cap$7.42 million OptionableNot Optionable Beta2.16 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Shai N. Gozani M.D. (Age 59)Ph.D., Founder, Chairman, CEO, President & Secretary Comp: $444.05kMr. Thomas T. Higgins (Age 72)Senior VP, CFO & Treasurer Comp: $347.75kDr. Xuan Kong Ph.D.Chief Data ScientistMs. Susan M. Bell R.N.Senior Vice President of Population Health & Value Based CareKey CompetitorsSpectral AINASDAQ:MDAIAutonomix MedicalNASDAQ:AMIXNeuroOne Medical TechnologiesNASDAQ:NMTCInspira Technologies Oxy B.H.N.NASDAQ:IINNFemasysNASDAQ:FEMYView All Competitors NURO Stock Analysis - Frequently Asked Questions How have NURO shares performed in 2024? NeuroMetrix's stock was trading at $3.60 on January 1st, 2024. Since then, NURO stock has increased by 2.5% and is now trading at $3.69. View the best growth stocks for 2024 here. Are investors shorting NeuroMetrix? NeuroMetrix saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 16,900 shares, an increase of 22.5% from the May 15th total of 13,800 shares. Based on an average daily volume of 19,200 shares, the days-to-cover ratio is currently 0.9 days. Approximately 1.1% of the shares of the company are short sold. View NeuroMetrix's Short Interest. When is NeuroMetrix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our NURO earnings forecast. How were NeuroMetrix's earnings last quarter? NeuroMetrix, Inc. (NASDAQ:NURO) released its quarterly earnings results on Wednesday, May, 15th. The medical device company reported ($1.67) EPS for the quarter. The medical device company earned $1.09 million during the quarter. NeuroMetrix had a negative net margin of 151.51% and a negative trailing twelve-month return on equity of 39.85%. When did NeuroMetrix's stock split? NeuroMetrix shares reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What is Shai N. Gozani's approval rating as NeuroMetrix's CEO? 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeuroMetrix own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Advanced Micro Devices (AMD) and Vaxart (VXRT). How do I buy shares of NeuroMetrix? Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NURO) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroMetrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroMetrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.